Comparative Pharmacology
Head-to-head clinical analysis: ERYC 125 versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC 125 versus ZITHROMAX.
ERYC 125 vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic